Zodasiran - Arrowhead Pharmaceuticals
Alternative Names: ARO-ANG3; ARO-ANG33; VSA-003Latest Information Update: 01 Jul 2025
At a glance
- Originator Roche
- Developer Arrowhead Pharmaceuticals
- Class Antihyperlipidaemics; Cardiovascular therapies; Small interfering RNA
- Mechanism of Action ANGPTL3 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hyperlipoproteinaemia type II
- Phase II Dyslipidaemias
Most Recent Events
- 25 Jun 2025 Arrowhead Pharmaceuticals plans a phase III trial for Hypercholesterolaemia (In adolescents, In adults, In elderly) in June 2025 (SC) (NCT07037771)
- 17 Jun 2025 Phase-III clinical trials in Hyperlipoproteinaemia type II (In adolescents, In the elderly, In adults) in USA (SC) (NCT07037771)
- 02 Dec 2024 Visirna Therapeutics plans a phase III trial for Hypercholesterolemia (In adolescents, In adults, In the elderly) in China (SC, Injection) (NCT06712771)